Pravastatin for the prevention of preeclampsia in high-risk pregnant women.

摘要: Preeclampsia complicates approximately 3-5% of pregnancies and remains one the major causes maternal neonatal morbidity. It shares pathogenic similarities with adult cardiovascular disease as well many risk factors. Attempts at prevention preeclampsia using various supplements classes medications have failed or had limited success, they were not convincing enough to lead widespread adoption any particular strategy. Contrary experience preeclampsia, mortality other events in nonpregnant patients 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors, statins, is widely accepted. Pravastatin statins been shown reverse pathophysiologic pathways associated such angiogenic imbalance, endothelial injury, inflammation, oxidative stress. These beneficial effects are likely contribute substantially preventing provide biological plausibility for use pravastatin this setting. has favorable safety pharmacokinetic profiles. In addition, animal studies human pregnancy exposure data do support teratogenicity claims pravastatin. Therefore, Eunice Kennedy Shriver National Institute Child Health Human Development Obstetric--Fetal Pharmacology Research Units Network started a pilot trial collect maternal--fetal evaluate pharmacokinetics when used prophylactic daily treatment high-risk pregnant women (identifier NCT01717586, clinicaltrials.gov).